Evidence map›Paper›PMID 39851060›Full record

ArticleJournal of clinical research in pediatric endocrinology2026

Cabergoline Induced Pathological Gambling in an Adolescent with Prolactinoma

Ummahan Tercan, Ezgi Sarban, Melek Yıldız, Özlem Nida Erbaşı, Mine Özkan, Aslı Derya Kardelen, Şükran Poyrazoğlu, Firdevs Baş, Feyza Darendeliler

Abstract readCase Reports
In one paragraph

Article in Journal of clinical research in pediatric endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ummahan Tercanİstanbul University, İstanbul Faculty of Medicine, Department of Pediatric Endocrinology, İstanbul, TürkiyeORCID 0000-0002-3240-3408
Ezgi Sarbanİstanbul University, İstanbul Faculty of Medicine, Department of Pediatric Endocrinology, İstanbul, TürkiyeORCID 0000-0002-8580-4504
Melek Yıldızİstanbul University, İstanbul Faculty of Medicine, Department of Pediatric Endocrinology, İstanbul, TürkiyeORCID 0000-0002-6603-2983
Özlem Nida Erbaşıİstanbul University, İstanbul Faculty of Medicine, Department of Child and Adolescent Psychiatry, İstanbul, TürkiyeORCID 0000-0002-4034-7100
Mine Özkanİstanbul University, İstanbul Faculty of Medicine, Department of Psychiatry, İstanbul, TürkiyeORCID 0000-0002-2981-9541
Aslı Derya Kardelenİstanbul University, İstanbul Faculty of Medicine, Department of Pediatric Endocrinology, İstanbul, TürkiyeORCID 0000-0003-0594-8741
Şükran Poyrazoğluİstanbul University, İstanbul Faculty of Medicine, Department of Pediatric Endocrinology, İstanbul, TürkiyeORCID 0000-0001-6806-9678
Firdevs Başİstanbul University, İstanbul Faculty of Medicine, Department of Pediatric Endocrinology, İstanbul, TürkiyeORCID 0000-0001-9689-4464
Feyza Darendelilerİstanbul University, İstanbul Faculty of Medicine, Department of Pediatric Endocrinology, İstanbul, TürkiyeORCID 0000-0003-4786-0780

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prolactinomas are the most common hormone-secreting pituitary adenomas in adolescents. Dopamine agonists (DA) are used as first-line medical treatment. DAs are associated with an array of physical side effects; however, impulse control disorders (ICDs), such as pathological gambling (PG), have also been reported in adults. A 15.7-year-old male with no psychiatric history was referred for headache and elevated prolactin (PRL) levels. He was diagnosed with PRL-secreting pituitary macroadenoma. After initiating DA therapy with cabergoline (CBG), normalization of PRL levels and a considerable decrease in tumor size were observed. Central hypothyroidism and adrenal insufficiency present at the time of diagnosis were resolved. CBG dose was adjusted according to the test results over time. However, after two and a half years of therapy (while using 1.5 mg CBG per week), the patient developed PG, incurring debts and affecting familial relationships. Upon reducing the CBG dosage, PG symptoms ceased. This is the first case report of an adolescent with a PRL-secreting macroadenoma who developed PG as a side effect of CBG treatment. This case highlights the need for careful monitoring of psychiatric symptoms in pediatric patients with prolactinoma on DAs.

Indexed as

Antineoplastic AgentsCabergolineDopamine AgonistsErgolinesGamblingPituitary NeoplasmsProlactinomaAdolescentHumansMaleAntineoplastic AgentsCabergolineDopamine AgonistsErgolinesAdolescentcabergolinedopamine agonistpathological gamblingprolactinoma

Identifiers

PMID39851060
PMCPMC13197093

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.